Abstract
The prognosis for patients with advanced gastric cancer (AGC) remains poor, and systemic chemotherapy is the main treatment option. Many clinical studies utilizing oxaliplatin-based regimens as first-line treatment for AGC have been conducted by Chinese investigators. However, there is no clear consensus concerning the role of oxaliplatin in AGC in Chinese patients. The aim of the present literature-based meta-analysis was to compare the efficacy and tolerability of oxaliplatin-based regimens with cisplatin-based regimens in Chinese patients with AGC. The search period included trials published between January 2003 and October 2007. A total of 116 trials were identified, of which 104 trials were excluded, and 12 trials were included in this meta-analysis. The present meta-analysis showed that oxaliplatin-based regimens may be associated with higher 1-year survival and objective response rates in Chinese patients with AGC compared with cisplatin-based regimens. Cisplatin was more frequently associated with nausea/vomiting and anemia, while peripheral neuropathy, which resolved over time, was more common with oxaliplatin. High quality, large-scale, randomized, controlled phase III trials are needed to accurately identify the therapeutic effect of oxaliplatin in Chinese patients with AGC.
Keywords: Advanced gastric cancer, oxaliplatin, cisplatin, Chinese
Current Cancer Therapy Reviews
Title: The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature
Volume: 6 Issue: 3
Author(s): Fenghua Wang, Fanggong Jiang, Yuhong Li, Ying Guo, Lin Shen and Li Zhang
Affiliation:
Keywords: Advanced gastric cancer, oxaliplatin, cisplatin, Chinese
Abstract: The prognosis for patients with advanced gastric cancer (AGC) remains poor, and systemic chemotherapy is the main treatment option. Many clinical studies utilizing oxaliplatin-based regimens as first-line treatment for AGC have been conducted by Chinese investigators. However, there is no clear consensus concerning the role of oxaliplatin in AGC in Chinese patients. The aim of the present literature-based meta-analysis was to compare the efficacy and tolerability of oxaliplatin-based regimens with cisplatin-based regimens in Chinese patients with AGC. The search period included trials published between January 2003 and October 2007. A total of 116 trials were identified, of which 104 trials were excluded, and 12 trials were included in this meta-analysis. The present meta-analysis showed that oxaliplatin-based regimens may be associated with higher 1-year survival and objective response rates in Chinese patients with AGC compared with cisplatin-based regimens. Cisplatin was more frequently associated with nausea/vomiting and anemia, while peripheral neuropathy, which resolved over time, was more common with oxaliplatin. High quality, large-scale, randomized, controlled phase III trials are needed to accurately identify the therapeutic effect of oxaliplatin in Chinese patients with AGC.
Export Options
About this article
Cite this article as:
Wang Fenghua, Jiang Fanggong, Li Yuhong, Guo Ying, Shen Lin and Zhang Li, The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in Advanced Gastric Cancer: A Systematic Review and Pooled Analysis of the Chinese Literature, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698188
DOI https://dx.doi.org/10.2174/157339410791698188 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Current Cancer Drug Targets Venoms and Poisonings during the Centuries: A Narrative Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry Profilin1 Sensitizes Pancreatic Cancer Cells to Irradiation by Inducing Apoptosis and Reducing Autophagy
Current Molecular Medicine Protective Effect of Annurca Apple Extract Against Oxidative Damage in Human Erythrocytes
Current Nutrition & Food Science Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer
Current Cancer Drug Targets Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach
Current Molecular Medicine Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design New Computational Approaches Aimed at the Prediction of More Selective and Active Drugs
Current Topics in Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition